Oslo, Norway, 21 April 2022 – Targovax ASA (OSE: TRVX) announces that the General Meeting has elected Dr Raphael Clynes and Mr Thomas Falck as new members of its Board of Directors.
Dr Clynes
Dr Clynes is an internationally recognized cellular immunologist and medical oncologist. Dr Clynes was on the faculty at the Columbia University where he developed several novel therapeutic approaches in cancer and autoimmunity. Since joining industry in 2014, Dr Clynes has led clinical immunotherapy development, including checkpoint inhibtors and novel CD3 bispecifics, at Bristol Myers Squibb (BMS) and at Xencor, where he is currently VP Translational Biology.
Dr Clynes is an MIT graduate and MSKCC-trained medical oncologist. As a well-recognized expert in clinical immunology, Dr Clynes has extensive prior experience as a contributing member of multiple scientific advisory boards in biopharma and review boards at international research foundations.
Mr Falck
Mr Falck is an experienced CEO, CFO, Board Chair and Non-Executive Director, Venture Capitalist & Growth Investor with demonstrated success in defining and delivering profitable growth while undertaking strategic and organizational change. He has broad experience with Private Equity, Venture Capital, Stock Listed, Family and Government owned entities.
Mr Falck holds an MBA from The Darden School at the University of Virginia and is a graduate of the Norwegian Naval Academy and the Norwegian Defence University College. In addition, Mr Falck has attended Executive Programs at Singularity University and Harvard Business School.
The Chairman of Board of Directors, Mr Damian Marron says: “We are very pleased to have attracted both Dr Clynes and Mr Falck as new members of the Board. Dr Clynes is a world-leading expert in immuno-oncology and his deep expertise in translational medicine will be instrumental as we push ONCOS-102 forward in the clinic and build our portfolio of next generation circular RNA pipeline candidates. Mr Falck is an experienced NED & Board Member, Investor, Advisor & Tech Executive, and whose strategic insight will be of great value for the Board.”
Raphael Clynes and Thomas Falck are replacing Per Samuelsson and Johan Christenson. Targovax expresses the company’s gratitude for the excellent work both has done as members of the Board over many years.
***
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
About Targovax
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax’s focus is to activate the patient’s immune system to fight cancer, and thereby bring benefit to cancer patients with few available treatment alternatives. Targovax is assessing its product candidates in different cancer indications, including melanoma, mesothelioma, and colorectal cancer, and has demonstrated a favorable safety and tolerability profile.
Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. On the back of very encouraging clinical data in several indications, both as monotherapy and in immunotherapy and chemotherapy combinations, the next development step for ONCOS-102 will be to further improve immune activation and clinical response in melanoma patients resistant to PD1 checkpoint blockade.
Building on successful phase 1/2 studies demonstrating clinical benefit and providing deep mechanistic insights, Targovax is expanding its ONCOS program into delivery of circular RNA and targeting KRAS mutant cancers with the aim of establishing a platform for development of a rich pipeline of innovative future immunotherapy product candidates.